Used in pharmaceutical research as a key intermediate in the development of kinase inhibitors, particularly targeting TRK (tropomyosin receptor kinase) proteins. It plays a role in the synthesis of compounds designed to treat cancers driven by NTRK gene fusions, such as certain types of lung, thyroid, and colorectal cancers. Its structure enables selective binding to TRK receptors, helping block signaling pathways that promote tumor growth. Also investigated for activity against resistant mutations in TRK-positive tumors, making it valuable in next-generation anticancer drug design.